Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000532706 | SCV000636797 | benign | Perlman syndrome | 2025-01-12 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000532706 | SCV000895421 | uncertain significance | Perlman syndrome | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000532706 | SCV003834688 | uncertain significance | Perlman syndrome | 2022-06-17 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003159799 | SCV003870018 | uncertain significance | Inborn genetic diseases | 2023-02-23 | criteria provided, single submitter | clinical testing | The c.662C>G (p.T221R) alteration is located in exon 7 (coding exon 6) of the DIS3L2 gene. This alteration results from a C to G substitution at nucleotide position 662, causing the threonine (T) at amino acid position 221 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Gene |
RCV003314611 | SCV004014248 | uncertain significance | not provided | 2023-07-14 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |